In anemic cancer patients treated with erythropoiesis-stimulating agent (ESA), (i) to examine the proportion of variance in hemoglobin (Hb) outcomes attributable to patients versus center, country, and region and (ii) to develop predictive models of treatment response. Results: Hb increased from 9.54 6 0.95 g/dl (baseline) to 10.88 6 1.49 g/dl (visit 3). Hb change from visits 1 to 2 (index of relative immediacy of response to ESA) averaged 0.81 6 1.17 g/dl. The proportion of variance in Hb outcomes attributable to center was 11.8%-34.3%, country 2.9%-20.7%, and region 0.0%-7.6%. Immediacy of response to ESA was the most prevalent predictor of treatment response, followed by diagnosis of hematological malignancy and age <70 years.
introduction
Despite the ongoing safety debate about the use of erythropoiesis-stimulating agents (ESAs) in cancer patients [1, 2] , these agents have been shown to be efficacious in improving hemoglobin (Hb) levels and alleviating anemia [3] -among the most prevalent side-effects of cancer and cancer treatment and associated with poor prognosis, impaired antineoplastic treatment outcomes, and reduced quality of life [4] [5] [6] [7] . The extant evidence base has enabled the development (and repeated updates) of practice guidelines both in Europe [8] [9] [10] and North America [11] [12] [13] . In 2001, only 17.4% of anemic cancer patients in Europe were treated with ESAs [14] , yet by 2007 this rate had increased about fourfold to 68.3% [15] . This rise may be attributed to the awareness about anemia in cancer patients raised by the European Cancer Anemia Survey (ECAS) study [14] and the clinical direction provided by evidence-based guidelines [8] [9] [10] [11] [12] [13] . Not only are more patients being treated with ESAs, but also treatment is increasingly in accordance with these guidelines [15] . Practicing in congruence with the erythropoietin guidelines of the European Organization for Research and Treatment of Cancer (EORTC) is a predictor of patients' Hb outcomes and achieving nonanemic Hb levels [16] .
Not all patients respond to ESA treatment. The Anemia Cancer Treatment (ACT) study, an international observational study on practice patterns and outcomes of ESA treatment original article *Correspondence to: Dr I. Abraham, Matrix45, 620 Frays Ridge Road, Earlysville, VA 22936, USA. Tel: +1-303-997-2697; Fax: +1-978-945-8374; E-mail: iabraham@ matrix45.com regimens, assessed ESA treatment response rates in anemic patients (Hb £ 11 g/dl) over three visits [15] . Five criteria of treatment response were applied. Almost two-thirds of patients (65.0%) showed an increase in Hb ‡1 g/dl over 8-10 weeks after initiation of ESA treatment, including 54.3% who reached this threshold by 8 weeks. Hematopoietic response (increase in Hb ‡2 g/dl or achieving Hb ‡12 g/dl) was observed in 38.9%, while a rise of Hb ‡2 g/dl was noted in 33.7% of patients. Only 18.8% reached the then prevailing EORTC-recommended range of 12-13 g/dl, now outside the approved label. Efforts at identifying determinants of response to ESA treatment have focused mainly on patient-level determinants. However, a significant proportion of variance in Hb outcomes may be attributable to center-level variables as patients seen in a given center are exposed to similar treatment patterns, are subjected to similar treatment protocols, and may be treated to varying degrees in accordance with evidence-based guidelines. Further, country and region of treatment may influence treatment outcomes because of differences in label and reimbursement. Using the European subsample of patients in the ACT study, we aimed (i) to quantify the variances in Hb outcomes by center, country, and region (Western versus Central/Eastern Europe) irrespective of any patient variables entering the equation and (ii) to develop clinically relevant models to predict response to ESA treatment.
methods
The background and methodology of the ACT study, patient disposition and sample derivation, patient demographics and characteristics, center characteristics, ESA treatment patterns, Hb outcomes, and treatment response rates have been described in detail elsewhere [15, 17] . Key sample and methodology points are summarized here.
design
Designed as a retrospective, multicenter, multilevel, longitudinal, observational pharmacoepidemiologic study based on medical records, ACT was an international study with 316 participating centers in 16 countries in Europe, Asia, and Latin America and a total of 2807 enrolled patients. The majority of centers (97.2%) and patients (95.9%) were from 13 Western, Central, and Eastern European countries. Data reported here are for the European subsample. The number of patients from other regions was too small to permit statistical analysis. ACT was an observational study of the 'real world' use of ESAs, hence there was no prescribed treatment regimen, no control, no scheduled intervention, and no randomization. sample Eligible for inclusion were the medical records of patients of age ‡18 years with a diagnosis of solid tumor (breast, bladder, cervix, colorectal, head/ neck, lung, ovary, or prostate) or myeloma or lymphoma, regardless of stage. Concomitant chemotherapy was not a requirement. Patients had to be anemic according to the then prevailing EORTC guidelines [8] (Hb £ 11 g/dl; note that this is 1 g/dl lower than the criteria used in other studies [14, 18] ) and started on any approved and marketed ESA. ESA treatment should have been initiated within 212 and 23 months preceding the start of the study. Data were required for a minimum of three (and optional up to five) clinic visits over an 8-to 10-week period in the previous 12 months. Ongoing ESA treatment was not required, only that ESA treatment was initiated at visit 1. Excluded were medical records of patients in whom ESA treatment was contraindicated, who had a previous diagnosis of a primary red blood cell disorder, and whose cause of anemia was not related to cancer or cancer treatment. All patients evaluated in this study were treated outside prospective clinical trials.
From an enrollment sample of 2807 patients, a European analysis sample of 2192 patients was derived [15] . To be included in this sample, patients had to meet inclusion and exclusion criteria, be treated in 1 of the 13 European countries included, and have valid Hb values for visits 1 through 3.
data model
Both center-and patient-level data were collected and are detailed elsewhere [15] . Summarized with regard to the data reported here, centerlevel data included country of origin, patient volume, thresholds for blood transfusion and ESA treatment, and use of anemia management protocols or guidelines. Achieving an Hb level between 12 and 13 g/dl (the then prevailing EORTC guideline, now outside the approved label) An increase in Hb ‡2 g/dl An increase in Hb ‡2 g/dl and/or attaining an Hb level ‡12 g/dl ('hematopoietic response') An increase in Hb ‡1 g/dl in a maximum of 8 weeks An increase in Hb ‡1 g/dl
statistical considerations
Per protocol, data from visits 1 through 3 constituted the primary analysis set. Data were analyzed in aggregate for all European countries as explained in greater detail elsewhere [15] . attribution of variance in Hb outcomes. It was assumed that the n j,k,l = 1, ., p j,k,l patients recruited by the jth center in the kth country in the lth region shared some proportion of variance in Hb outcomes related to the class effect of their common center, country, and region of treatment. We determined the proportions of variance in Hb outcomes attributable to center, country, and region by means of unconditional two-level hierarchical modeling with estimation using restricted maximum likelihood. The intraclass correlation coefficient (ICC), the index of attributable variance (range 0.00-1.00; convertible to percentage 0-100), was calculated as the ratio of the intercept covariance parameter to the total covariance parameters in the fixed effects component of the mixed model. The ICC quantifies the overall magnitude of the class effect.
modeling of treatment response rates. Logistic regression (P in = 0.05, P out = 0.10) was applied to identify patient-and center-related determinants of response to ESA treatment. Country of treatment was considered as a potential determinant as well.
ethics and study management
The study was conducted in accordance with the World Medical Association's Declaration of Helsinki. The study protocol was reviewed in each participating center and approval was obtained in accordance with the applicable local laws and regulations. 
ESA treatment and Hb outcomes
Summarized (analyses reported in this paper built on results already reported [15] ), Hb increased from 9.54 6 0.95 g/dl at baseline to 10.88 6 1.49 g/dl at visit 3. A small proportion of patients (241 or 11.0%) had received a blood transfusion before ESA initiation. Only 608 patients (27.7%) received iron supplementation at visit 1, mainly in oral formulation (81.8%). Initial ESA treatment included epoetin alfa (20.7% of patients), epoetin beta (42.6%), darbepoetin alfa (36.4%), and other ESAs (0.3%), mainly on a fixed dose (96.7%) and once-weekly regimen (65.7%). Standardized to IU/ week, median dosage was 30 000 IU/week. Change in Hb levels from visits 1 to 2, an index of immediacy of response to ESA treatment, ranged from 24.60 to 6.70 g/dl with mean of 0.81 (SD = 1.17, 95% confidence interval 0.76-0.85). Table 3 summarizes the ICCs for various Hb outcomes by center, country, and region (Western versus Central/Eastern Europe). The proportion of variance in Hb outcomes attributable to treatment center ranged from 11.8% to 34.3%, to country from 2.9% to 20.7%, and to region from 0.0% to 7.6%. modeling of treatment response Table 4 presents the logistic regression models for the five criteria of treatment response, including predictors, odds ratios (ORs), goodness-of-fit statistics, and Nagelkerke R 2 coefficients. Two variables should be considered proxies of aspects of clinical status: performance status (WHO/ECOG 0 or 1 versus 2 or worse) as a proxy of cancer-related disability and change in Hb from visits 1 to 2 as a proxy of immediacy of response to ESA therapy.
attribution of variance in Hb outcomes

discussion
The ACT study, an observational study of effectiveness outcomes of ESAs in real world clinical practice, documents the original article Annals of Oncology extent to which clinical awareness and evidence-based guidelines have translated into treatment patterns (ESAs, blood transfusion, and iron supplementation), Hb outcomes, and response to ESA treatment [15] . This article is the first to report the proportion of variability in Hb outcomes attributable to center, country, and region of treatment-before any patient variables enter into the equation. It also identified independent predictors of response to ESA treatment. Our data question the common practice of attributing ESA treatment failure to patient-specific characteristics only. Though patient-related determinants constitute the single largest class impacting Hb outcomes, there is heterogeneity in treatment patterns across These findings point at the significant impact that centerlevel policies, protocols, and treatment patterns exert on Hb outcomes and underscore the importance of following evidence-based guidelines. Greater convergence across centers in the management of anemia through the use of evidencebased guidelines is likely to decrease the current heterogeneity and therefore the amount of variance in Hb outcomes that can be attributed to center.
The logistic models of treatment response rates (using five different criteria) revealed some important factors. The change observed in Hb from the start of ESA treatment to the next visit 3 to 4 weeks later (i.e. the relative immediacy of response to ESA) consistently emerged as the single most important factor in subsequent treatment response. This finding is consistent with those from other observational studies [19] [20] [21] [22] [23] [24] but not necessarily prospective trials [25, 26] . The higher the Hb change immediately following initiation of ESA, the higher the likelihood (ORs ranging from 2.78 to 9.59) of reaching any of the five criteria of treatment response. Important in itself, this is even more critical considering that concomitant chemotherapy tends to be associated with a suppression of Hb of 21 g/dl, thus creating an even greater barrier to be overcome in a patient's trajectory to nonanemic status.
In this process of regaining nonanemic status, patients with a hematological malignancy may have an edge over those diagnosed with solid tumors. This may be due to the trend toward higher ESA dosing in these patients, their higher likelihood of presenting with absolute erythropoietin deficiency, and the fact that they are being seen by hematologists. In addition, hematological patients (lymphoma, chronic myeloid leukemia, and multiple myeloma) tend to show higher response rates to chemotherapy compared with patients with solid tumors. Patients responding to chemotherapy probably have less tumor-reduced suppression of hematopoiesis and less impairment of iron utilization, resulting in increased erythropoiesis. Other determinants associated with greater odds of treatment response, though not as consistently as initial Hb response and tumor category, included being <70 years old (two of five criteria), as well as starting Hb, limited disability secondary to chronic disease, and a center's typical trigger Hb to initiate ESA treatment (one criterion each). Age as a risk factor for poor response is consistent with prior findings [27] , as is impaired performance status [28] .
A few odds-lowering effects were observed, but none of these were clinically surprising. Higher Hb levels at start of ESA therapy were associated with a lower likelihood of achieving a ‡1 g/dl rise in the first 8 weeks (OR = 0.86), most likely because there was less room for improvement. If ESA treatment was initiated at Hb ‡10 g/dl, the odds of achieving a ‡2 g/dl improvement were diminished (OR = 0.57)-especially if this patient was treated in a Western European country where starting Hb levels tend to be higher to begin with (OR = 0.74). Lastly, a patient who started on ESA treatment at Hb ‡9 dl was less likely to attain hematopoietic response (OR = 0.52).
Critically, it should be noted that these rates are lower than those observed in prospective randomized trials. One reason may be that the duration of ESA therapy was not predefined by protocol and hence for many patients much shorter than in prospective trials. As treatment was per clinicians' best judgment, this study did not specify dose-escalating procedures, though these were not discouraged either. Possibly, more patients might have benefited from dose increases. No Hb target was imposed and satisfaction with treatment results was an individual physician judgment. Many prospective trials used different definitions of treatment response than the dichotomous variables used in this analysis. The greatest incremental increase in quality of life is seen when Hb is pushed from 10 to 11 g/dl. This target was reached in a substantial number of patients, thus reducing the need for further Hb increases. There was variability in adherence to evidence-based guidelines across centers if not countries. Lastly, the patients in the ACT study were vastly more heterogeneous than those enrolled in prospective trials.
Calling for greater adherence to evidence-based guidelines may be professionally 'de rigueur'; however, the clinical reality in medicine in general [29] , and oncology [30] in particular, is equivocal. In a different but related study, however, we recently showed the relationship between practicing in congruence with the 2006 EORTC guidelines [9] and Hb outcomes [16] . Using a 0-10 scale to quantify the extent to which an anemic patient was being managed in accordance with the guidelines, it was found that an one-point increase in scores was associated with a 0.60 g/dl higher Hb at month 4 and a 0.56 g/dl higher change in Hb from month 1 to 4. Each one-point improvement increased the odds of reaching Hb ‡11 g/dl by 3.14 and Hb ‡12 g/dl by 2.77.
The ACT study has limitations and provides direction for future studies. Being a retrospective chart review, ACT did not include safety data. It was assumed that clinicians would adhere to voluntary reporting laws in their respective countries. The current debate as to the safety of ESAs in general and in specific tumor types needs to be integrated into observational studies. Such studies will enable further safety monitoring. Importantly, they will allow the evaluation of safety outcomes as a function of variability in ESA treatment, not just ESA treatment in itself (as in randomised, controlled trials), and under consideration of many potential determinants and confounds. Thus, future studies should quantify the clinical benefits versus clinical risks of ESA treatment to supersede current qualitative arguments to that extent. Follow-up was limited to two required visits after ESA initiation. Longer studies will permit assessment of the extent to which nonanemic status is maintained once it has been achieved. Though no significant differences were noted relative to the sample at large, representation of centers and patients from France and Germany was disproportionate to other countries. Future studies should endeavor to achieve more balanced and representative distributions.
In conclusion, the ACT study shows a significant change in anemia treatment patterns from the ECAS with almost four times as many anemic cancer patients being treated with ESAs compared with 2001, though not with the iron supplementation regimens that clinical experience and emerging evidence suggests might be indicated. However, there is still wide variability in treatment patterns and outcomes in Europe with the proportion of variance in Hb outcomes attributed to treatment center ranging from 12%-34%. The immediacy of response to ESAs was the single most important predictor of treatment response, followed by diagnosis of hematological malignancy, starting Hb level, and age <70 years. Even though more patients are treated with ESAs today, there remains significant room for improvement in outcomes, adherence to guidelines, and the likely interaction of both. 
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